CN Patent

CN114787152A — 一种bms-986165晶型及其制备方法和用途

Assigned to Crystal Pharmaceutical Suzhou Co Ltd · Expires 2022-07-22 · 4y expired

What this patent protects

化合物I的晶型及其制备方法，含有该晶型的药物组合物，以及该晶型在制备TYK2抑制剂药物和治疗银屑病、系统性红斑狼疮和克罗恩病药物中的用途。化合物I的结晶比现有技术具有一种或多种改进的性质，对未来该药物的优化和开发具有重要价值。

USPTO Abstract

化合物I的晶型及其制备方法，含有该晶型的药物组合物，以及该晶型在制备TYK2抑制剂药物和治疗银屑病、系统性红斑狼疮和克罗恩病药物中的用途。化合物I的结晶比现有技术具有一种或多种改进的性质，对未来该药物的优化和开发具有重要价值。

Drugs covered by this patent

Patent Metadata

Patent number
CN114787152A
Jurisdiction
CN
Classification
—
Expires
2022-07-22
Drug substance claim
No
Drug product claim
No
Assignee
Crystal Pharmaceutical Suzhou Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.